CheckMate 816: three cycles of nivolumab plus chemotherapy before lung cancer surgery
Just three cycles of chemotherapy with the immunotherapy nivolumab before surgery wiped out all viable tumour in a quarter of patients and reduced relapse or death by about a third, without making surgery harder.
Open-label phase 3 trial of 358 patients with resectable stage IB-IIIA NSCLC randomised to three cycles of neoadjuvant nivolumab plus platinum-doublet chemotherapy or chemotherapy alone, followed by surgery. Primary endpoints were pathological complete response (pCR) and event-free survival (EFS).
pCR was 24.0% vs 2.2% and median EFS 31.6 vs 20.8 months (HR 0.63). Surgery rates and complications were not worse with nivolumab. A 2025 report confirmed an overall survival benefit (HR about 0.72). It was the first neoadjuvant immunotherapy approval in lung cancer and, together with the perioperative trials (KEYNOTE-671, AEGEAN, CheckMate 77T), moved immunotherapy before surgery.
- Pathological complete response 24.0% vs 2.2% (odds ratio 13.9).
- Median event-free survival 31.6 vs 20.8 months; HR 0.63 (97.38% CI 0.43-0.91).
- Definitive surgery was performed in 83% vs 75% of patients; grade 3-4 surgery-related adverse events 11% in both arms.
- Patients achieving pCR had markedly better EFS (HR about 0.13 within the nivolumab arm).
- Overall survival (2025 update): HR about 0.72, with 5-year OS of roughly 65% vs 55%.
Patients with operable stage II-III lung cancer without EGFR or ALK alterations should have chemo-immunotherapy discussed before surgery rather than only afterwards. Three pre-operative cycles do not compromise the operation and improve cure rates. Whether to continue immunotherapy after surgery, as the perioperative trials do, and whether patients with pCR need any further treatment, remain open questions.
- Open-label; EFS by blinded review.
- About one in six patients did not proceed to surgery in either arm, an under-appreciated risk of any neoadjuvant strategy.
- Benefit was smaller in stage IB-II and in PD-L1-negative tumours.
- No adjuvant immunotherapy was given, so the trial cannot say whether the perioperative approach adds value over neoadjuvant alone.
Pages like this
not linked directly; found by shared links- Key paperNIAGARA: durvalumab before and after cystectomy for muscle-invasive bladder cancer
Shares Event-free / disease-free survival (EFS, DFS, iDFS, RFS), Pathologic complete response (pCR), Neoadjuvant / adjuvant / perioperative, Dormant cells and minimal residual disease.
- TrialCheckMate 816
Shares Patrick M. Forde, Pathologic complete response (pCR), Neoadjuvant / adjuvant / perioperative, Nivolumab.
- Key paperKEYNOTE-522: adding pembrolizumab before and after surgery in early triple-negative breast cancer
Shares Event-free / disease-free survival (EFS, DFS, iDFS, RFS), Pathologic complete response (pCR), Paclitaxel / nab-paclitaxel, Carboplatin.
- Key paperNADINA: two doses of ipilimumab plus nivolumab before surgery beat a year of nivolumab after surgery in stage III melanoma
Shares Event-free / disease-free survival (EFS, DFS, iDFS, RFS), Pathologic complete response (pCR), Neoadjuvant / adjuvant / perioperative, Bristol Myers Squibb.
- Key paperKEYNOTE-189: pembrolizumab plus chemotherapy as first treatment for non-squamous lung cancer without a driver mutation
Shares Enriqueta Felip, Carboplatin, No one can predict who responds to immunotherapy, Cytotoxic chemotherapy.
- Key paperNICHE-2: a month of nivolumab and ipilimumab before surgery clears mismatch-repair-deficient colon cancer in most patients
Shares Pathologic complete response (pCR), Neoadjuvant / adjuvant / perioperative, Bristol Myers Squibb, No one can predict who responds to immunotherapy.
- Key paperTopalian 2012: the first large trial of a PD-1 antibody shows durable responses across melanoma, lung and kidney cancer
Shares Julie R. Brahmer, Bristol Myers Squibb, No one can predict who responds to immunotherapy, Nivolumab.
- Key paperRUBY: dostarlimab with chemotherapy for advanced or recurrent endometrial cancer
Shares Paclitaxel / nab-paclitaxel, Carboplatin, No one can predict who responds to immunotherapy, Cytotoxic chemotherapy.